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of needed raw data, r can be computed from relative risks, odds ratios, t statistics,
F statistics, chi square statistics, standard normal deviate Z statistics, and beta
coefficients. In studies reporting p-values only, p-values can be converted to their
associated one-tailed standard normal deviate Z values to allow the calculation of
r. Before computed r’s can be combined, theymust be transformed using the Fisher
Z transformation in order to normalize their distribution. The weighted and un-
weighted Fisher Z transformed r’s are then converted back to r’s, and the weighted
and unweighted mean r’s are calculated. Confidence intervals around these esti-
mates show the degree to which they significantly differ from zero. For the un-
weighted mean r, the random effects confidence interval is usually preferred. Al-
though such confidence interval tends to be wider, it allows generalization to
studies other than those included in the sample. This methodology is demon-
strated using a dataset from a systematic review of published scientific literature.
The analysis shows how diversely-reported effects sizes can be converted and
combined to produce a summary r, which explains the association between spe-
cific determinant and outcome variables. Despite the value of correlation r inmeta-
analysis, it continues to be underused in the synthesis of scientific evidence.
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DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS: HOW CAN
BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?
Kirpekar S, Dummett H
Double Helix Consulting, London, UK
Data requirements from reimbursement authorities globally vary greatly due to
variation in importance of HTA and levels of acceptable complexity in submitted
economic evidence. Oftenmarket differences have been addressed by global phar-
maceutical companies by developing value arguments that address the most de-
veloped reimbursement systems, which then have to be adapted locally, often
resulting in the duplication of effort among local affiliates. Placing customer re-
quirements and informal preferences as the starting point of the development of
value arguments can increase efficiency and more specifically meet local HTA
needs. Methodologies that will support development of locally adaptable value
arguments – both value dossiers as well as health economic messages - requires
first of all the understanding of local payer needs. Countries requiring submission
of economic data can be classified on the basis of commonly required assessment
methods – budget impact analysis, cost effectiveness analysis and cost minimisa-
tion analysis, as well as the complexity accepted in both submitted clinical and
economic evidence. This complexity is in terms of level of complexity of data
requirements for Health Economic analysis, technical modelling approach, CE out-
come, local/international data preference, preference for comparator, preferred
time horizon amongst others. This can be used to divide these countries into buck-
ets with similar requirements. Globally developed value arguments can be devel-
oped and adapted to these buckets of countries and their needs. Basing value
arguments that are developed globally as mentioned, and then sent to local affili-
ates to adapt to the specific needs of their HTA system, on the preferences of
customers is expected to be crucial to ensure local success for reimbursement.
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DESIGN AND OPERATIONAL CONSIDERATIONS FOR PRAGMATIC CLINICAL
TRIALS TO SUPPORT HEOR EVALUATIONS
Ishak KJ1, Payne KA1, Schrammel M2, Caro JJ3
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Unlike randomized controlled trials (RCTs), pragmatic clinical trials (PCTs) mea-
sure the relative benefits of competing treatments in actual practice, thus, are an
important pharmacoeconomic data source. Depending on the design features, tri-
als can vary in their degree of pragmatism. We undertook a brief review of the
literature to highlight specific PCT design considerations that optimize their utility
for health economic and outcomes research (HEOR) applications. A broad popula-
tion and active control groups, typical in PCTs, can help achieve generally repre-
sentative HEOR assessments and reduce reliance upon indirect comparisons. A
minimally restrictive protocol is needed to preserve a naturalistic focus, and for
reducing Hawthorne effects. Some control is required, however, tominimize study
biases. Randomization to initial treatment choice remains essential to avoid selec-
tion bias and confounding, but little control should be exerted on regimen changes
so that real-world prescribing patterns (switching, adding, and dropping) patterns
and patient behaviors (non-compliance, non-adherence) can be evaluated. In the
absence of blinding, ascertainment bias is also a risk; use of objectively measured
outcomes that may even be identifiable from medical charts can help. Capturing
clinical, resource utilization, safety, preference, and quality of life, outcomes can
lead to richer economic models, and better understanding of usual-care treatment
decisions. With a broad patient base, it is important to explore subgroup effects,
and to prioritize predictive analyses to identify response variation. Beyond a
thoughtful study design, key operational elements such as site selection, patient
recruitment and retention and ongoing study support are critical to PCT success.
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TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL
IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH
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Themajority of new PROmeasures are developed in English, with a small minority
developed in other languages. This poses the question of how to translate and
linguistically validate measures developed in languages other than English, when
the resources are simply not available for translating from the source language (e.g.
Hungarian) into the target language (e.g. Bengali). The URAM Scale assesses func-
tional performance of the hand in patients with Dupuytren’s Contracture. It was
developed in French and initially translated and linguistically validated into UK
English. Themethodology employed for this translationwas the reverse of a typical
English to French translation, whereby the French in-country investigator acted as
the project manager and an in-house project manager (qualified in French to Eng-
lish translation) acted as the in-country investigator. The translation into English
required consultation with the developer and two issues needed to be resolved in
order to develop the UK English version. One item required alternative wording as
it mentioned wash mitts, which are very rarely used in the UK, and for another
item, two verbs were required to convey the meaning of a single French verb. On
completion of the translation, the UK English version was then used as a source
version for the translation of the URAM Scale into several other European lan-
guages. During this process the translators were asked to work from the English
version but to also consider the relevance of the original Frenchwording for the two
items that required a change in English. For example, in countries where wash
mitts are used, this wording was retained instead of the new English wording
which used ‘flannel’. This experience highlights the importance of always consid-
ering the original development language when translating a measure using a gen-
erated English version as the source.
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CHEMOTHERAPY INDUCED NAUSEA AND VOMITING EVENT RATE AMONG
PATIENTS WITH CANCER TREATED WITH HIGHLY OR MODERATELY
EMETOGENIC CHEMOTHERAPY AND INITIATED ON PALONOSETRON VERSUS
OTHER 5-HT3-RECEPTOR ANTAGONIST ANTI-EMETIC PROPHYLAXIS IN A
HOSPITAL OUTPATIENT SETTING
Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc., Charlotte, NC, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: To assess the rate of chemotherapy induced nausea and vomiting
(CINV) associatedwith palonosetron (a 5-hydroxy tryptamine3-receptor antagonist
[5-HT3-RA]) initiation versus other 5-HT3-RAs among patients with cancer on
highly [HEC] or moderately emetogenic chemotherapy (CT) [MEC] treatment in a
hospital outpatient setting.METHODS: Patients with a cancer diagnosis initiating
HEC or MEC and anti-emetic prophylaxis with palonosetron (Group 1) or other
5-HT3-RAs (Group 2) for the first time (index date) between 4/1/2007 – 3/31/2009
were identified from the Premier Perspective comparative database. Inclusion cri-
teria were patients aged 18 yearswith no evidence of nausea and vomiting or use
of HEC/MEC or anti-emetic medication in the 6-month pre-index date period, and
with 36-consecutive months of hospital data. Follow-up time was first of eight CT
cycles (a cycle was the unit of analysis) or six months post-index date. A negative
binomial distribution generalized linear multivariate regression model estimating
the CINV event rate on CT matched groups in the follow-up period was developed
after controlling for demographic and clinical variables. RESULTS: Of 6418 identi-
fied patients, 1522 (23.7%) initiated palonosetron. Group 1 patients comprised of
less African Americans (8.7% vs. 14.2%) and more Hispanics (5.7% vs. 4.5%);
p0.0001, more patients on HEC [50.5% vs. 41.5%; p0.0001], and more non-colon
gastrointestinal (10.3% vs. 6.3%) and breast cancer patients (19.5% vs. 16.8%);
p0.0001. In the follow-up period, the number of unadjusted CINV events between
the matched groups was lower for Group 1 [6957 vs. 7784; p0.054] patients. The
regressionmodel predicted a significant decrease (12.5%) in the CINV event rate per
CT cycle for Group 1 patients versus Group 2 patients; p0.0044. CONCLUSIONS: In
this retrospective hospital outpatient study, patientswith cancer treatedwithHEC/
MEC and initiated on palonosetron were more likely to experience a significantly
lower rate of CINV events versus those initiating other 5-HT3-RAs.
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O’Mara S1, Fitton S1, Hayers J1, Tham C1, Wei R4, Luka A4, Neary MP6, Duh MS4
1University of Manchester, Manchester, UK, 2Singleton Hospital, Swansea, UK, 3Mount Vernon
Cancer Center, Northwood, Middlesex, UK, 4Analysis Group, Inc., Boston, MA, USA, 5Analysis
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OBJECTIVES: This study evaluated the rates of and reasons for treatment modifi-
cations and occurrence of adverse events (AEs) among patients treated with anti-
angiogenic agents in UK clinical practice. METHODS: Data from medical records
were retrospectively reviewed at 3 large UK oncology centers for mRCC patients
who were 18 years and received sunitinib (N90) as first-line treatment from
January 1, 2005 to October 15, 2010. Proportions of patients with treatment modi-
fications (i.e.: discontinuation, interruption, or dose change) and reasons for mod-
ifications were determined. Time to treatment discontinuation and proportion of
patients with all grade and grade 3/4 AEs were also determined. Data on clinician
assessed response rates was collected. RESULTS: Ten percent of patients were
cytokine-pretreated. Average daily dose over initial cycle was 31.98 mg; 77.8% of
patients started treatment with recommended dosing of 50 mg QD 4/2. Among the
62 patients with available tumor response assessments, 35.5% had an objective
response (OR; complete or partial response). A total of 84.4% of patients experi-
enced AEs; 24.4% experienced grade 3/4 AEs. The most commonly reported all
grade AEs were diarrhea (35.6%), mucositis/stomatitis (34.4%), and fatigue (26.7%);
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43.3% of patients had a dose reduction. Adverse events led to treatment modifica-
tions in 60.0% of patients. Among patients who discontinued treatment, 27.3%
discontinued within 18 weeks (9.1% in 0-6 weeks, 6.1% in 7-12 weeks, and 12.1% in
13-18 weeks). Among those who discontinued, 30.3% discontinued due to AEs.
CONCLUSIONS: Objective response rate (35.5%) was higher than that observed in
expanded access trial (17%) but lower than that observed in randomized clinical trial.
A large proportion (60%) of patients experienced treatment modifications due to AEs.
About 15.2% of treatment discontinuations occurred within the first two cycles. This
real-worldclinicalpractice studysuggests that tolerabilitywithsunitinib isachallenge
for physicians in the clinical care of mRCC patients in the UK.
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CARDIOVASCULAR COMORBIDITIES AMONG PATIENTS WITH METASTATIC
COLORECTAL CANCER
Overbeek JA1, Zhao Z2, van Herk-Sukel MPP1, Barber BL2, Gao S2, Herings RMC1
1PHARMO Institute, Utrecht, The Netherlands, 2Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: To determine the rate of comorbid cardiovascular diseases in pa-
tients with metastatic colorectal cancer (mCRC), as comorbidities may impact
treatment decisions, prognoses, and quality of care.METHODS: From the PHARMO
Record Linkage System (RLS), including among other things, drug dispensing and
hospitalisation records of approximately 3.2 million residents in The Netherlands,
all patients with a primary or secondary hospital discharge code for CRC and dis-
tant metastasis between 2000 and 2008 were selected and defined as patients with
mCRC. The first discharge diagnosis defining metastases served as the index date.
Prevalent cardiovascular comorbidities were assessed during the 12 months prior
to the index date and patients were required to be registered in the PHARMORLS in
this period to be included in the study cohort. Cardiovascular comorbidities were
captured using information on drugs dispensed for the treatment of cardiovascular
diseases in the outpatient setting, which include antihypertensive agents, anti-
thrombotic agents, agents acting on the renin-angiotensin system, and cardiac
therapy. Results were summarised descriptively by the number and proportion of
patients receiving these agents. RESULTS:A total of 2,964 patientswithmCRCwere
included in the analysis. Mean ( standard deviation) age at diagnosiswas 68 ( 12)
years and 53% were male. Overall, cardiovascular comorbidities were observed in
50% of the patients, with 27% having diseases requiring antithrombotic treatment
(such as arterial thromboembolism, strokes, and deep vein thrombosis) and 11%
having cardiac therapy. CONCLUSIONS: Cardiovascular comorbidities are com-
monly seen in patientswithmCRC,whichmight be explained by the highmean age
at diagnosis. Consideration of these conditions should be an integral part of the
treatment strategy in individual patients with mCRC.
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BODY MASS INDEX AND STAGE OF DIAGNOSIS OF OVARIAN CANCER: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Blieden MB
Harvard University, Boston, MA, USA
OBJECTIVES: The majority of ovarian cancer cases are not diagnosed until late
stages, which carry dramatically greater risk of death. Obese women experience
higher rates of ovarian cancer, and are at higher risk of ovarian cancer mortality.
Delayed diagnosis of ovarian cancer in obesewomenmay explain this relationship.
METHODS: A MEDLINE search was performed to systematically identify articles
that present stage of diagnosis of ovarian cancer by BMI. We included 7 of 252
articles identified in the search, and conducted a meta-analysis of 3,275 cases of
ovarian cancer in these 7 studies to determine if there was an association between
stage at diagnosis and BMI. RESULTS: 74% of cases were diagnosed at a late stage;
15% had a BMI of at least 30 kg/m2. The data showed a significant downward trend
in proportion of late-stage cases by BMI. Patientswhowere underweightweremost
likely to be diagnosed at a late stage (81%). Women with higher BMIs were less
likely to be diagnosed at a late stage, with 72% of overweight women and 71% of
obese women having stage III/IV ovarian cancer (p0.009). The odds of late-stage
disease were lower in high-BMI women compared to the odds of late-stage disease
in women with a normal BMI (OR0.783; 95%CI: 0.623-0.987). CONCLUSIONS:
These findings suggest a modest inverse association between BMI and stage at
diagnosis. This is contrary to the hypothesized relationship, and could be ex-
plained by diagnostic differences, increased symptoms of ovarian cancer in the
obese, tumor characteristics, or cancer-related weight loss. Future studies should
investigatewhy obesewomen have highermortality rates despite earlier diagnosis
of ovarian cancer.
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USING HEALTH CLAIMS DATA TO STUDY PATTERNS OF CERVICAL CANCER
SCREENING AND DIAGNOSIS IN A STATE MEDICAID FEE-FOR-SERVICE
POPULATION (FUNDING: AHRQ – P20-HS15930)
Nadpara P1, Madhavan S1, Khanna R2, Atkins E1, Smith MJ3, Miller LA1
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OBJECTIVES: Cervical cancer (CC) is the 11th most common cancer among Ameri-
can women. In West Virginia (WV), it is second most common cancer and also
second leading cause of cancer-related mortality in 25-44 years aged women. The
study objective was to use claims data for surveillance of CC and precancerous
cervical intraepithelial lesions (PCL) among women enrolled in the state Medicaid
Fee-For-Service program. METHODS: Enrollment, demographic, and claims data
for continuously enrolled female recipients aged 18-64 years for the period 2003 to
2008 were analyzed for this study. All medical claims were aggregated to reflect
each recipient’s medical utilization. RESULTS: Pap smear testing prevalence de-
clined between 2003 (238.9/1,000) and 2008 (158.8/1,000). During the study period,
approximately 58% women had at least 1 Pap smear test. While prevalence of CC
diagnosis declined from 139 to 113 during the study period, the prevalence of
cervical intraepithelial neoplasia-1 (CIN1) and CIN2 increased to 85 and 207 from
2003 to 2008, respectively. Approximately 73% of the women received Pap testing
during the 365 day period prior to their index date of CC or PCL diagnosis. Poisson
regression model found age, race, location, contraceptive use, access to provider
and co-morbidity status as significant (p.05) predictors of persistence with Pap
testing. Ordinal logistic regression model predicted Pap screening persistence as a
significant factor that was associated with the likelihood of an initial diagnosis of
CC, high grade PCL, or low grade PCL. Only 10% of the women received appropriate
follow-up care following a diagnosis of low grade PCL; for high grade PCL diagnosis
32% of the women received appropriate follow-up care. CONCLUSIONS: The study
found declining screening rates for CC during the study period in fee-for-service
Medicaid population. Disparities in appropriate follow-up care following a diagno-
sis of high grade or low grade PCL were also identified.
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BREAST, PROSTATE AND COLORECTAL CANCER SCREENING BEHAVIOR AND
INCIDENCE OF LATE STAGE CANCER DIAGNOSIS IN ELDERLY WEST
VIRGINIANS
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OBJECTIVES: Age-adjusted all-site cancer incidence and overall cancer mortality
rates are higher in West Virginia (WV) compared to the US. Population-based
screening is an effective tool that helps in early detection\treatment of cancer.
However, incidence of late-stage diagnosis remains frequent among screening-
amenable cancers in WV. The objective of this study is to identify: (1) breast, pros-
tate and colorectal cancer screening-behavior and (2) factors associated with late-
stage breast, prostate and colorectal cancer diagnosis among elderly West
Virginians.METHODS: Cancer stage and demographic information for individuals
with incidence of breast, prostate or colorectal cancer during years 2002-2005 were
extracted from theWVCancer Registry (WVCR) database. Data on cancer screening
behavior were obtained from Behavioral Risk Factor Surveillance System (BRFSS)
survey for 2002-2005. RESULTS: Age-adjusted late-stage colorectal cancer inci-
dence rates were significantly higher inWV compared to the US population during
2002-2005. Invasive incidence rates (per 100,000) were higher among both men
(WV: 67.0; US: 56.4) and women (WV: 44.2; US: 41.9). Nearly half of all colorectal
cancers were diagnosed at regional or distant stage. WV rates for late-stage breast
and prostate cancer incidence were lower compared to US. Screening rates for all 3
cancers in WV were lower compared to US; Colorectal Cancer (46.3% vs. 53.8%),
Breast Cancer (72.5% vs. 74.6%), Prostate Cancer (59.7% vs. 61.6%). CONCLUSIONS:
Unlike CDC report [MMWR-2010;59(No.SS-9)], West Virginians in this study had
lower incidence of late-stage Breast and Prostate Cancer compared to US. However,
colorectal cancer late- stage incidence rates remained higher inWVvs. theUS. This
difference in late-stage cancer incidence rates might be explained partially by dif-
ferences in screening use, which also remained lower for all three cancers in WV
compared to US. Patient, provider and health care system related factors may
account for variation in the proportion of populations that get screened.
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COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB
IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL
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Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, 5Thoracic Hospital of Heidelberg
GmbH, Heidelberg, Germany
OBJECTIVES: A biological and genetical variation of lung cancer is non-small cell
lung cancer (NSCLC) bearing activatingmutations in the tyrosine kinase domain of
the epidermal growth factor receptor (EGFR m). In this population the EGFR ty-
rosine kinase inhibitors (TKIs) erlotinib and gefitinib have shown significant in-
crease in progression-free survival (PFS) compared to chemotherapy. Erlotinib is
not yet licensed for this indication; however, an EMA marketing authorization
submission is currently ongoing. Therefore both therapies will be competing to be
primary choice in treatment naïve patients with EGFR m NSCLC; hence, in the
absence of direct head-to-head comparison, there is a need for indirect treatment
comparison (ITC) assessment. METHODS: Published phase-III evidence was used
as the basis for the ITC. The Bucher et al. ITC methodology was applied to the PFS
hazard ratios (HRs) obtained by comparing the TKIs versus chemotherapy. Erlotinib
obtained a HR of 0.16 (95%CI: 0.10-0.26, p0.0001) based on the OPTIMAL trial;
gefitinib obtained the following PFS HRs vs. chemotherapy: IPASS trial: 0.48 (95%CI:
0.36-0.64, p0.001); WJTOG trial: 0.33 (95%CI: 0.20-0.54, p0.0001) and NEJGSG trial:
0.30 (95%CI: 0.22-0.41, p0.001). Besides comparing the erlotinib PFS HR with each
single gefitinib trial, erlotinib was compared to the pooled gefitinib evidence.
RESULTS: Comparing the PFS HRs of erlotinib versus gefitinib based on the OPTIMAL
trial and the IPASS trial resulted in a statistically significant PFS difference (ITC HR:
0.33; 95%CI: 0.19-0.58; p0.0001). This statistically significant PFS difference was
also observed when comparing OPTIMAL versus WJTOG (ITC HR: 0.48; 95%CI: 0.24-
0.97, p0.0395) and versus NEJGSG (ITC HR: 0.53; 95%CI: 0.30-0.9, p0.0307). Com-
paring erlotinib vs. the pooled gefitinib phase-III evidence confirmed these
findings. CONCLUSIONS: According to the underlying indirect comparison of pub-
lished phase-III evidence, erlotinib is the most efficacious EGFR TKI in first-line
EGFR m NSCLC.
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